Covered recipient · General Payments record
ROBERT J BUYNAK
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,542.53
14 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,686.01 | 5 |
| Food and Beverage | $856.52 | 9 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,306.50 | 8 |
| Amgen Inc. | $1,236.03 | 6 |
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT J BUYNAK
NPI 1508977984 · CMS profile ID 340544
Allopathic & Osteopathic Physicians / Internal Medicine
VALPARAISO, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508977984?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
14 matching records · $2,542.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–14 of 14.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $36.80 | 07/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226894486 | CMS |
| Amgen Inc. | $83.73 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228433454 | CMS |
| Amgen Inc. | $256.01 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228433458 | CMS |
| Amgen Inc. | $374.98 | 07/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226896770 | CMS |
| Amgen Inc. | $382.11 | 07/23/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226896772 | CMS |
| Amgen Inc. | $102.40 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228433456 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49.26 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921001 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38.18 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921003 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38.18 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921005 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $78.82 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921007 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $129.89 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921009 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $80.05 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921011 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $501.14 | 04/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921015 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $390.98 | 02/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222921013 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,038,550.53 | 603 |
| PY2024 | Principal investigator | $5,031,915.33 | 601 |
| PY2023 | Recipient | $906.71 | 2 |
| PY2023 | Principal investigator | $4,138,599.32 | 2,384 |
| PY2022 | Recipient | $3,104.59 | 10 |
| PY2022 | Principal investigator | $5,204,363.35 | 1,133 |
| PY2021 | Principal investigator | $3,348,948.64 | 610 |
| PY2020 | Recipient | $1,489.26 | 13 |
| PY2020 | Principal investigator | $1,938,354.41 | 292 |
| PY2019 | Recipient | $658.79 | 10 |
| PY2019 | Principal investigator | $1,439,149.33 | 218 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
601 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157090 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 12/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157092 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157094 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157096 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $690.62 | 12/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 1155802320 |
| Principal investigator 1 | ModernaTX, Inc. | $40,185.00 | 12/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142768 |
| Principal investigator 1 | ModernaTX, Inc. | $91,174.35 | 12/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142942 |
| Principal investigator 1 | ModernaTX, Inc. | $44,313.70 | 12/20/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147184221 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $962.00 | 12/19/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520143 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,158.41 | 12/19/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089521308 |
| Principal investigator 1 | Novo Nordisk AS | $2,200.00 | 12/19/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096772653 |
| Principal investigator 1 | ModernaTX, Inc. | $260,870.00 | 12/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142722 |
| Principal investigator 1 | ModernaTX, Inc. | $81.96 | 12/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180219 |
| Principal investigator 1 | ModernaTX, Inc. | $132,702.65 | 12/17/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142910 |
| Principal investigator 1 | Novo Nordisk AS | $13,561.52 | 12/12/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096861662 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 12/11/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180217 |
| Principal investigator 1 | ModernaTX, Inc. | $49.89 | 12/10/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147180215 |
| Principal investigator 1 | Novo Nordisk AS | $1,154.00 | 12/10/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096798910 |
| Principal investigator 1 | ModernaTX, Inc. | $27,358.75 | 12/04/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147184219 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 12/02/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184215 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/02/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184217 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157086 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 11/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157088 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157098 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157100 |
| Principal investigator 1 | ModernaTX, Inc. | $75.13 | 11/29/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180199 |
| Principal investigator 1 | ModernaTX, Inc. | $587,670.00 | 11/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142514 |
| Principal investigator 1 | ModernaTX, Inc. | $28,260.60 | 11/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142654 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147184191 |
| Principal investigator 1 | ModernaTX, Inc. | $2,325.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147184193 |
| Principal investigator 1 | ModernaTX, Inc. | $3,300.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147184195 |
| Principal investigator 1 | ModernaTX, Inc. | $753.38 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147184197 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 11/22/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147184199 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,147.00 | 11/21/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519743 |
| Principal investigator 1 | ModernaTX, Inc. | $16,919.00 | 11/21/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147184211 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 11/15/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180197 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 11/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184205 |
| Principal investigator 1 | ModernaTX, Inc. | $1,800.00 | 11/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184207 |
| Principal investigator 1 | ModernaTX, Inc. | $1,746.00 | 11/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184209 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $8,856.34 | 11/14/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089521023 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,200.00 | 11/14/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089521114 |
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 11/14/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130987418 |
| Principal investigator 1 | ModernaTX, Inc. | $5,505.16 | 11/08/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147184189 |
| Principal investigator 1 | ModernaTX, Inc. | $7,000.00 | 11/08/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age | No dispute reported | 06/30/2026 | 1147184213 |
| Principal investigator 1 | PFIZER INC. | $4,725.00 | 11/08/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130987423 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 11/06/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184201 |
| Principal investigator 1 | ModernaTX, Inc. | $2,700.00 | 11/06/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147184203 |
| Principal investigator 1 | ModernaTX, Inc. | $5,054.40 | 11/01/2024 | Non-covered Recipient Entity Velocity Clinical Research, Valparasio | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147184187 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157082 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 10/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157084 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157102 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157104 |
| Principal investigator 1 | Eli Lilly and Company | $195.00 | 10/31/2024 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1137350367 |
| Principal investigator 1 | ModernaTX, Inc. | $561.00 | 10/30/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147180175 |
| Principal investigator 1 | ModernaTX, Inc. | $7,550.00 | 10/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142164 |
| Principal investigator 1 | ModernaTX, Inc. | $6,650.00 | 10/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142166 |
| Principal investigator 1 | ModernaTX, Inc. | $3,325.00 | 10/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142168 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,605.50 | 10/24/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519819 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,400.00 | 10/24/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520056 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $7,700.00 | 10/24/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520794 |
| Principal investigator 1 | ModernaTX, Inc. | $102.45 | 10/22/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180177 |
| Principal investigator 1 | Seqirus USA Inc | $194.40 | 10/21/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123451247 |
| Principal investigator 1 | Seqirus USA Inc | $3,794.85 | 10/21/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123451255 |
| Principal investigator 1 | ModernaTX, Inc. | $40,394.00 | 10/16/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147135269 |
| Principal investigator 1 | ModernaTX, Inc. | $99.78 | 10/16/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147180173 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 10/16/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130993100 |
| Principal investigator 1 | ModernaTX, Inc. | $6,800.00 | 10/14/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142322 |
| Principal investigator 1 | ModernaTX, Inc. | $19,200.00 | 10/09/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147142134 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 10/09/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147142232 |
| Principal investigator 1 | Eli Lilly and Company | $204.52 | 10/08/2024 | Non-covered Recipient Entity MEHRDAD KEVIN ARIANI MD | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1137363067 |
| Principal investigator 1 | ModernaTX, Inc. | $7,053.79 | 10/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147135197 |
| Principal investigator 1 | ModernaTX, Inc. | $833.62 | 10/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147135209 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156926 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156928 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157048 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157050 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157052 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157054 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157056 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157058 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157060 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157062 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157064 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157066 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157068 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157070 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157072 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157074 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157076 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 09/30/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147142100 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,450.00 | 09/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1110842419 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,246.19 | 09/26/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520643 |
| Principal investigator 1 | ModernaTX, Inc. | $49,333.80 | 09/25/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134967 |
| Principal investigator 1 | ModernaTX, Inc. | $11,502.56 | 09/25/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141970 |
| Principal investigator 1 | PFIZER INC. | $10,360.00 | 09/25/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131018826 |
| Principal investigator 1 | Seqirus USA Inc | $4,998.43 | 09/25/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450995 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,624.60 | 09/20/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1110836952 |
| Principal investigator 1 | ModernaTX, Inc. | $3,917.22 | 09/18/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141936 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123449355 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450799 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450801 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450803 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450805 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450807 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450809 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450811 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450813 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450815 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450817 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450819 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450821 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450823 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450825 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450827 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450829 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450831 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450833 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450835 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450837 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450839 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450841 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450843 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450845 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450847 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450849 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450851 |
| Principal investigator 1 | Seqirus USA Inc | $703.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450853 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450855 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450857 |
| Principal investigator 1 | Seqirus USA Inc | $121.00 | 09/18/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123450859 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 09/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147180151 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 09/12/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141932 |
| Principal investigator 1 | ModernaTX, Inc. | $5,054.40 | 09/11/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134969 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $975.00 | 09/05/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519540 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 09/04/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157326 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/04/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141900 |
| Principal investigator 1 | PFIZER INC. | $6,660.00 | 09/04/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131018820 |
| Principal investigator 1 | ModernaTX, Inc. | $1,792.70 | 09/03/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134971 |
| Principal investigator 1 | ModernaTX, Inc. | $59,993.48 | 09/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141854 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156922 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156924 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157018 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157020 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157022 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157024 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157026 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157028 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157030 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157032 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157034 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157036 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157038 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157040 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157042 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157044 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157046 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,234.00 | 08/26/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1110845727 |
| Principal investigator 1 | Mylan Specialty L.P. | $10,110.44 | 08/26/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1141407902 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/20/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147180139 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 08/14/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157334 |
| Principal investigator 1 | ModernaTX, Inc. | $56,177.50 | 08/14/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134641 |
| Principal investigator 1 | ModernaTX, Inc. | $859.29 | 08/09/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134479 |
| Principal investigator 1 | ModernaTX, Inc. | $236.25 | 08/09/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134489 |
| Principal investigator 1 | ModernaTX, Inc. | $75.00 | 08/09/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134491 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 08/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134493 |
| Principal investigator 1 | ModernaTX, Inc. | $9,251.55 | 08/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134499 |
| Principal investigator 1 | ModernaTX, Inc. | $18,954.00 | 08/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134607 |
| Principal investigator 1 | Seqirus USA Inc | $20,693.40 | 08/02/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123448915 |
| Principal investigator 1 | ModernaTX, Inc. | $4,704.75 | 08/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147134377 |
| Principal investigator 1 | ModernaTX, Inc. | $33,551.72 | 08/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147134439 |
| Principal investigator 1 | ModernaTX, Inc. | $14,502.34 | 08/01/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141642 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156918 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156920 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156930 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156932 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156934 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156936 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156938 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156940 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156942 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156944 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156946 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156948 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156950 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156952 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156954 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156956 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156958 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156960 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121157078 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121157080 |
| Principal investigator 1 | Novo Nordisk AS | $2,200.00 | 07/24/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096748375 |
| Principal investigator 1 | Novo Nordisk AS | $13,561.52 | 07/24/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096796231 |
| Principal investigator 1 | Novo Nordisk AS | $1,154.00 | 07/24/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096820853 |
| Principal investigator 1 | ModernaTX, Inc. | $1,074.12 | 07/19/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134063 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $24,200.00 | 07/18/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089520277 |
| Principal investigator 1 | ModernaTX, Inc. | $75,501.25 | 07/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147134155 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 07/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123448767 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 07/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123448803 |
| Principal investigator 1 | ModernaTX, Inc. | $1,503.76 | 07/05/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147134043 |
| Principal investigator 1 | PFIZER INC. | $41,877.80 | 06/29/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131067259 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156878 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156880 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156882 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156884 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156886 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156888 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156890 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156892 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156894 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156896 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156898 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156900 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156902 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156904 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156906 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156908 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156910 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156912 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156914 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156916 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $54,668.40 | 06/26/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1110840348 |
| Principal investigator 1 | ModernaTX, Inc. | $8,438.85 | 06/26/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147133775 |
| Principal investigator 1 | ModernaTX, Inc. | $1,263.60 | 06/26/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147133829 |
| Principal investigator 1 | ModernaTX, Inc. | $72,770.00 | 06/20/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147133861 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447107 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447117 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447898 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447900 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447965 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447967 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447969 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447971 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447973 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447975 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447977 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447979 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447981 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447983 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447985 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447987 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447989 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447991 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447993 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447995 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447997 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447999 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448001 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448003 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448005 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448007 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448009 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448613 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448615 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448617 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448619 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448621 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448623 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448625 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448627 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 06/19/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123448629 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,950.00 | 06/13/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519368 |
| Principal investigator 1 | ModernaTX, Inc. | $58,208.89 | 06/05/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147133655 |
| Principal investigator 1 | ModernaTX, Inc. | $26,239.72 | 06/05/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147133657 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156796 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156802 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156804 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156806 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156808 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156810 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156812 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156814 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156816 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156818 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156820 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156822 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156824 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156842 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156846 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156852 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156854 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156856 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156858 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156876 |
| Principal investigator 1 | ModernaTX, Inc. | $47,517.97 | 05/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141392 |
| Principal investigator 1 | ModernaTX, Inc. | $100.50 | 05/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - VALPARAISO | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147180137 |
| Principal investigator 1 | Novo Nordisk AS | $9,792.00 | 05/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096832091 |
| Principal investigator 1 | ModernaTX, Inc. | $13,783.05 | 05/29/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147133437 |
| Principal investigator 1 | ModernaTX, Inc. | $129,036.45 | 05/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147133473 |
| Principal investigator 1 | Seqirus USA Inc | $979.20 | 05/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | No dispute reported | 06/30/2026 | 1123447109 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,860.00 | 05/10/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1089696559 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,111.32 | 05/08/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 1110846433 |
| Principal investigator 1 | Novo Nordisk AS | $432.00 | 05/08/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096735490 |
| Principal investigator 1 | Novo Nordisk AS | $2,739.96 | 05/07/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096731344 |
| Principal investigator 1 | Novo Nordisk AS | $442.44 | 05/07/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096800122 |
| Principal investigator 1 | Novo Nordisk AS | $432.00 | 05/07/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096824383 |
| Principal investigator 1 | Novo Nordisk AS | $3,888.36 | 05/06/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096752367 |
| Principal investigator 1 | Novo Nordisk AS | $1,738.08 | 05/06/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096874157 |
| Principal investigator 1 | Novo Nordisk AS | $3,597.48 | 05/03/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096872379 |
| Principal investigator 1 | ModernaTX, Inc. | $1,719.36 | 05/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141332 |
| Principal investigator 1 | Novo Nordisk AS | $4,167.72 | 05/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096740338 |
| Principal investigator 1 | Novo Nordisk AS | $4,656.60 | 05/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096813871 |
| Principal investigator 1 | Novo Nordisk AS | $358.56 | 05/02/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096824062 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,229.00 | 05/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157142 |
| Principal investigator 1 | Novo Nordisk AS | $5,019.48 | 05/01/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096853911 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156794 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156798 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156800 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156826 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156828 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156830 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156832 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156834 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156836 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156838 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156840 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156844 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156848 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156850 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156860 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156862 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156864 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156866 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156868 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156870 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156872 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156874 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 04/26/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1147132821 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $13,500.00 | 04/25/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1089519175 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $48,325.55 | 04/19/2024 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128703324 |
| Principal investigator 1 | ModernaTX, Inc. | $6,718.73 | 04/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147132921 |
| Principal investigator 1 | ModernaTX, Inc. | $95,689.12 | 04/15/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147132973 |
| Principal investigator 1 | PFIZER INC. | $20,000.00 | 04/13/2024 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131087767 |
| Principal investigator 1 | ModernaTX, Inc. | $29,991.92 | 04/10/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147132891 |
| Principal investigator 1 | ModernaTX, Inc. | $77,010.00 | 04/10/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147133123 |
| Principal investigator 1 | ModernaTX, Inc. | $18,301.68 | 04/05/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147132865 |
| Principal investigator 1 | ModernaTX, Inc. | $2,778.00 | 04/05/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147141138 |
| Principal investigator 1 | ModernaTX, Inc. | $24,119.66 | 04/05/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147141208 |
| Principal investigator 1 | ModernaTX, Inc. | $84,498.40 | 04/03/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147133061 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157144 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157146 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157148 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157150 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157152 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157154 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157156 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,237.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157158 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157160 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157162 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,121.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157164 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157168 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,121.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157170 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157172 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157174 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,121.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157176 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,750.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157178 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157180 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157182 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157184 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,121.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157186 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157188 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157190 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $292.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157192 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $144.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157200 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,750.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157292 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157294 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,543.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157296 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157298 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,971.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157300 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157302 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157306 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,750.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157308 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157310 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,543.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157312 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,253.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157314 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,460.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121157316 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $13,652.00 | 04/01/2024 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1078938776 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156574 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156576 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156578 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156580 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156582 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156584 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156586 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156588 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156590 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156626 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156628 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156634 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156636 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156638 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156640 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156642 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156644 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156646 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156648 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156650 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156652 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156654 |
| Principal investigator 1 | ModernaTX, Inc. | $38,819.35 | 03/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147140998 |
| Principal investigator 1 | PFIZER INC. | $15,000.00 | 03/28/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131104479 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 03/28/2024 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1131104485 |
| Principal investigator 1 | ModernaTX, Inc. | $2,970.00 | 03/27/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147132453 |
| Principal investigator 1 | ModernaTX, Inc. | $90,979.20 | 03/27/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147132603 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 03/25/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156994 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,248.00 | 03/25/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156996 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $21,624.00 | 03/25/2024 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1078938754 |
| Principal investigator 1 | ModernaTX, Inc. | $25,172.59 | 03/21/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147140906 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $846.00 | 03/18/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156986 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,499.00 | 03/18/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121157008 |
| Principal investigator 1 | ModernaTX, Inc. | $151,282.50 | 03/15/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147132559 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444848 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444854 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444860 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444868 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444970 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444976 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444984 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123444988 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445130 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445132 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445134 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445136 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445138 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445140 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445142 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445144 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445146 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445148 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445150 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445152 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445154 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445156 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445158 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445160 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445162 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445164 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445166 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445168 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445170 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445172 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445174 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445176 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445178 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445180 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445182 |
| Principal investigator 1 | Seqirus USA Inc | $50.60 | 03/15/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123445184 |
| Principal investigator 1 | Novavax Inc | $39,963.00 | 03/14/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123376101 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $89,454.00 | 03/13/2024 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1078938780 |
| Principal investigator 1 | ModernaTX, Inc. | $81,072.38 | 03/08/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147132411 |
| Principal investigator 1 | ModernaTX, Inc. | $87,318.87 | 03/08/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147132413 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $146.00 | 03/06/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156962 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $72.00 | 03/06/2024 | Non-covered Recipient Entity Velocity Clinical Research Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156964 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,667.22 | 03/05/2024 | Non-covered Recipient Entity BUYNAK CLINICAL RESEARCH PC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1089696615 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $320,765.80 | 03/02/2024 | Non-covered Recipient Entity Velocity Clinical Research Durham | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101071869 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $286,148.60 | 03/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Durham | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101071333 |
| Principal investigator 1 | ModernaTX, Inc. | $12,739.16 | 03/01/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147132431 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156656 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156658 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156660 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156662 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156664 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156666 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156762 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156764 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156766 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156768 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156770 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156772 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156774 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156776 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156778 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156780 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156782 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156784 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156786 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156788 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156790 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156792 |
| Principal investigator 1 | Novo Nordisk AS | $442.44 | 02/29/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096780327 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 02/28/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147132247 |
| Principal investigator 1 | ModernaTX, Inc. | $40,904.07 | 02/28/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147140736 |
| Principal investigator 1 | Novo Nordisk AS | $26,544.37 | 02/27/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 1096849905 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,593.08 | 02/26/2024 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101070931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,802.08 | 02/26/2024 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101071867 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 02/23/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 1096850308 |
| Principal investigator 1 | ModernaTX, Inc. | $15,787.61 | 02/21/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147132375 |
| Principal investigator 1 | ModernaTX, Inc. | $37,482.30 | 02/21/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147140716 |
| Principal investigator 1 | Novavax Inc | $5,735.00 | 02/21/2024 | Non-covered Recipient Entity PREFERRED RESEARCH PARTNERS INC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123374517 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,750.00 | 02/14/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1110840938 |
| Principal investigator 1 | ModernaTX, Inc. | $36,333.70 | 02/14/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147132125 |
| Principal investigator 1 | ModernaTX, Inc. | $87,213.75 | 02/14/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147132191 |
| Principal investigator 1 | Eli Lilly and Company | $60,181.00 | 02/13/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1137370532 |
| Principal investigator 1 | Novavax Inc | $3,918.00 | 02/07/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger than 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1123375021 |
| Principal investigator 1 | Novavax Inc | $300.00 | 02/07/2024 | Non-covered Recipient Entity SANDHILL RESEARCH LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | No dispute reported | 06/30/2026 | 1123377209 |
| Principal investigator 1 | ModernaTX, Inc. | $37,206.00 | 02/02/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | No dispute reported | 06/30/2026 | 1147132249 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156568 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156570 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156572 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156592 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156594 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156596 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156598 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156600 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156602 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156604 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156606 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156608 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156610 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156612 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156614 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156616 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156618 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156620 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156622 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121156624 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156630 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Velocity Clinical Research,Valparaiso | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121156632 |
| Principal investigator 1 | Eli Lilly and Company | $1,772.72 | 01/31/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1137370544 |
| Principal investigator 1 | Novo Nordisk AS | $3,888.36 | 01/29/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | NN9535-4321 | No dispute reported | 06/30/2026 | 1096815946 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,824.21 | 01/26/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 1110842608 |
| Principal investigator 1 | Eli Lilly and Company | $9,264.70 | 01/26/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | AN OPEN-LABEL, SINGLE-ARM, PHASE 4 STUDY TO ASSESS GLYCEMIC CONTROL WHEN ADULTS WITH TYPE 2 DIABETES SWITCH FROM A GLP-1 RA TO TIRZEPATIDE (SURPASS-SWITCH-2) | No dispute reported | 06/30/2026 | 1137369712 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 01/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147131835 |
| Principal investigator 1 | ModernaTX, Inc. | $1,800.00 | 01/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147131837 |
| Principal investigator 1 | ModernaTX, Inc. | $9,516.00 | 01/24/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147131839 |
| Principal investigator 1 | ModernaTX, Inc. | $87,435.00 | 01/17/2024 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | No dispute reported | 06/30/2026 | 1147131599 |
| Principal investigator 1 | ModernaTX, Inc. | $67,324.44 | 01/16/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147140438 |
| Principal investigator 1 | Seqirus USA Inc | $167.50 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123440600 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123441998 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442004 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442006 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442012 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442026 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442032 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442046 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442048 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442052 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442415 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442429 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442447 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442467 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442469 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442477 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442489 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442493 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442505 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442511 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442819 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442821 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442823 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442825 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442827 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442829 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442831 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442833 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442835 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442837 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442839 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442841 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442843 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442845 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442847 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442849 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442851 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442853 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442855 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442857 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442859 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442861 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442863 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442865 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442867 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442869 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442871 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442873 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442875 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442877 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442879 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442881 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442883 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442885 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442887 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442889 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442891 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442893 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442895 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442897 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442899 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442901 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442903 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442905 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442907 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442909 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442911 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442913 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442915 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442917 |
| Principal investigator 1 | Seqirus USA Inc | $587.00 | 01/12/2024 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1123442919 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,943.72 | 01/10/2024 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU | No dispute reported | 06/30/2026 | 1127525834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,703.10 | 01/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | phase III efficacy for obesity - with T2DM | No dispute reported | 06/30/2026 | 1101068871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,803.62 | 01/01/2024 | Non-covered Recipient Entity Velocity Clinical Research Valparaiso | Phase III efficacy for obesity - without T2DM | No dispute reported | 06/30/2026 | 1101068929 |